This Project Grant award of $884,453.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a rapid, cost-effective point-of-care (POC) test for detecting the hepatitis C virus (HCV). The project, titled "Rapid Point of Care Hepatitis C Virus Detection Using a Long-Lasting Luminescent Cascade Signal Amplification," is being conducted by Brigham & Women's Hospital...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $876,400 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Notre Dame DU Lac to develop a novel point-of-care diagnostic assay for rapid assessment of hepatitis C virus (HCV) viral load and associated liver disease. The project aims to integrate Janus bead technology and virus ultrafiltration to create a 30-minute, one-step assay that can quantify HCV viral load...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a low-cost, instrument-free rapid antigen test for active Hepatitis C Virus (HCV) infection. The $272,133 award to Rutgers, The State University of New Jersey will fund research activities over a period of approximately 2 years, from June 2025 to May 2027. The key objectives are to characterize the...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop an economical, rapid, and accurate molecular test for detecting hepatitis C virus (HCV) and HIV infections from whole blood samples. The $1,361,442 award to Emory University will fund research to: 1) automate and streamline RNA sample extraction and stabilization technology for HCV and HIV RNA...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $592,027 to Northwestern University to develop and validate a point-of-care molecular diagnostic test for active hepatitis C virus (HCV) infection. The key products and services to be delivered include: Development of the "DASH HCV" test that can rapidly detect HCV viral RNA from a simple finger-stick blood sample, without the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop an integrated biosensor technology for the simultaneous detection of HIV, hepatitis B, and hepatitis C viruses. The $537,619 award, spanning from March 2025 to February 2028, will support the University of Central Florida's research to integrate their recently developed four-way junction (4WJ) electrochemical...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,413,007.00 to the University of Washington to develop and evaluate an ultra-sensitive CRISPR-based diagnostic tool called CRISPR-TB. The goal is to enable early and accurate detection of tuberculosis (TB) in children under 5 years old, a population that is disproportionately impacted by TB but least likely...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of a novel universal rapid test for HIV diagnosis. IGE Immunodiagnostics & Therapeutics, LLC, a minority-owned small business, will receive $294,948 to adapt their existing HIV ELISA test into a 5th generation antigen/antibody combination rapid test format. The goal is to create a simple, rapid,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $466,500.00 to support the development of a rapid and ultrasensitive aptamer-based detection technology for Treponema pallidum, the causative agent of syphilis. The goal is to create an inexpensive, point-of-care diagnostic test that can accurately diagnose syphilis in both adults and congenital cases, enabling...
This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,012,033 to the University of Washington to develop a point-of-care nucleic acid amplification test (NAAT) for rapid, on-site diagnosis of hepatitis C virus (HCV) infection. The proposed diagnostic test aims to address the challenge of delayed HCV testing and treatment by enabling same-day identification of active HCV infection from a simple whole blood sample, without the need for complex laboratory equipment. The test is designed to be low-cost, easy-to-use, and CLIA-waived, facilitating expanded access to HCV diagnosis and treatment, particularly in resource-limited outpatient settings. The University of Washington has sub-awarded a portion of the grant to the nonprofit organization PATH to support the development and testing of this innovative HCV diagnostic technology. This project aligns with broader initiatives to eliminate HCV as a public health threat by improving access to rapid, decentralized testing capabilities.